Breaking News, Financial News

Financial Report: Roche 1H11

Group sales were stable in local currencies, up 2%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche 1H11* YTD Revenues: 21.7 billion (-12%) YTD Earnings: 5.3 billion (-5%) Comments: Group sales, excluding Tamiflu, were up 2% in local currencies to 21.4 billion. Pharmaceutical sales were down 11% to 16.8 billion (-1% in LC). The decrease in Avastin and Tamiflu sales, generic competition for CellCept, and competition for the NeoRecormon/Epogin franchise, was partially offset by continued growth of Herceptin, MabThera/Rituxan, Xeloda and Tarceva, Lucentis and Actemra/RoActemra. R&D c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters